Krystal Biotech (NASDAQ:KRYS) Receives Buy Rating from Stifel Nicolaus

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reiterated by Stifel Nicolaus in a report issued on Tuesday, Benzinga reports. They currently have a $204.00 price objective on the stock, up from their prior price objective of $178.00. Stifel Nicolaus’ target price would indicate a potential upside of 20.25% from the stock’s previous close.

A number of other equities research analysts have also weighed in on KRYS. Citigroup boosted their target price on shares of Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Guggenheim boosted their price target on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Finally, William Blair restated an “outperform” rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, Krystal Biotech currently has an average rating of “Buy” and an average target price of $164.22.

Krystal Biotech Price Performance

KRYS opened at $169.64 on Tuesday. Krystal Biotech has a fifty-two week low of $82.09 and a fifty-two week high of $189.97. The firm has a market capitalization of $4.84 billion, a price-to-earnings ratio of 2,120.77 and a beta of 0.85. The company’s 50 day moving average price is $157.74 and its two-hundred day moving average price is $129.49.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, February 26th. The company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.82. The business had revenue of $42.14 million for the quarter, compared to the consensus estimate of $27.43 million. During the same period in the previous year, the firm earned ($1.25) earnings per share. As a group, equities research analysts predict that Krystal Biotech will post 1.61 EPS for the current year.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the transaction, the insider now owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Krystal Biotech news, CAO Kathryn Romano sold 8,087 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $136.91, for a total transaction of $1,107,191.17. Following the transaction, the chief accounting officer now owns 12,556 shares in the company, valued at $1,719,041.96. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the transaction, the insider now owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The disclosure for this sale can be found here. Insiders have sold 40,587 shares of company stock worth $6,535,591 in the last quarter. Company insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of KRYS. Vanguard Group Inc. raised its holdings in Krystal Biotech by 40.7% during the third quarter. Vanguard Group Inc. now owns 2,400,142 shares of the company’s stock worth $278,416,000 after buying an additional 693,852 shares during the last quarter. Jennison Associates LLC raised its holdings in Krystal Biotech by 112.5% during the fourth quarter. Jennison Associates LLC now owns 724,344 shares of the company’s stock worth $89,862,000 after buying an additional 383,495 shares during the last quarter. State Street Corp raised its holdings in Krystal Biotech by 52.3% during the first quarter. State Street Corp now owns 1,068,656 shares of the company’s stock worth $71,108,000 after buying an additional 366,855 shares during the last quarter. First Turn Management LLC acquired a new position in Krystal Biotech during the fourth quarter worth $30,045,000. Finally, Balyasny Asset Management L.P. raised its holdings in Krystal Biotech by 686.1% during the fourth quarter. Balyasny Asset Management L.P. now owns 256,604 shares of the company’s stock worth $31,834,000 after buying an additional 223,962 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).